Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 4;21(9):1372-1382.
doi: 10.1002/cbic.201900623. Epub 2020 Jan 20.

Calcium Regulates S100A12 Zinc Sequestration by Limiting Structural Variations

Affiliations

Calcium Regulates S100A12 Zinc Sequestration by Limiting Structural Variations

Qian Wang et al. Chembiochem. .

Abstract

Antimicrobial proteins such as S100A12 and S100A8/A9 are highly expressed and secreted by neutrophils during infection and participate in human immune response by sequestering transition metals. At neutral pH, S100A12 sequesters Zn2+ with nanomolar affinity, which is further enhanced upon calcium binding. We investigated the pH dependence of human S100A12 zinc sequestration by using Co2+ as a surrogate. Apo-S100A12 exhibits strong Co2+ binding between pH 7.0 and 10.0 that progressively diminishes as the pH is decreased to 5.3. Ca2+ -S100A12 can retain nanomolar Co2+ binding up to pH 5.7. NMR spectroscopic measurements revealed that calcium binding does not alter the side-chain protonation of the Co2+ /Zn2+ binding histidine residues. Instead, the calcium-mediated modulation is achieved by restraining pH-dependent conformational changes to EF loop 1, which contains Co2+ /Zn2+ binding Asp25. This calcium-induced enhancement of Co2+ /Zn2+ binding might assist in the promotion of antimicrobial activities in humans by S100 proteins during neutrophil activation under subneutral pH conditions.

Keywords: NMR spectroscopy; S100 metalloproteins; S100A12; nutritional immunity; zinc sequestration.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
A) The primary sequence of human S100A12 showing Zn2+ binding residues (colored cyan) and EF hand loops. The secondary structure elements are presented above the sequence and displayed as blue bar for helices, pink arrows for β-strand and cyan line for loops; B) an expansion of Zn2+ bound S100A12 crystal structure showing the zinc binding site (PDB: 2WCB). The two monomers are colored blue and gray. The zinc and sodium ions are colored purple and blue, respectively and; C) an overlay of the crystal structures of apo S100A12 (PDB: 2WCF, blue) and Ca2+ bound S100A12 (PDB: 1E8A, orange). The EF-hand loops are colored using the same color scheme as in (A).
Figure 2.
Figure 2.
Overlay of 14.1 T 1H-15N HSQC spectra of the S100A12 at pH 8.3 (blue), 6.0 (pink) and 4.5 (light green) for A) apo-protein and, B) calcium bound S100A12. The residues involved in His3Asp Zn2+ binding motif are labeled in red.
Figure 3.
Figure 3.
pH dependence of Co2+ binding to S100A12 in the absence (orange) and presence (blue) of Ca2+ shown with a plot of absorbance at 556 nm versus pH. At pH values greater than 7.3 minor protein precipitation in the calcium bound S100A12 was observed that interfered with the baselines of the absorption spectra, giving rise to irregular absorption maxima under these conditions.
Figure 4.
Figure 4.
1H-15N HMQC spectra showing the tautomeric forms of histidine residues in (A) apo (16.8 T) and; (B) calcium bound S100A12 (14.1 T) at pH 7.5 (orange) and 6.0 (blue). The cross-peak patterns belonging to a single residue are marked with colored boxes.
Figure 5.
Figure 5.
2D and 3D 1H, 15N, 13C experiments conducted for the assignments of histidine sidechain nuclei of calcium bound S100A12 at pH 6.0. A) 1H-15N HMQC; B) 2D 1H-13C (HB)CB(CDCGCD)HD; C) a strip plot of the 3D HN(CO)CACB (blue) and HNCACB (red) spectra; D) a strip plot of the 1H-15N NOESY-HSQC (orange) spectrum. Resonances associated with a residue are labeled and marked with same color across all spectra.
Figure 6.
Figure 6.
Site specific absolute values of chemical shift perturbation between pH 6.0 and 7.0 for (A) Cα and, (B) NH nuclei in the absence (pink) or presence (blue) of calcium ion. The negative values represent residues for which resonance assignments are not available. The secondary structure of the apo-protein determined from the crystal structure (PDB code 2WCF) is displayed at the top: α-helices (blue bars), β-strands (pink arrows), and loop regions (cyan lines). The values 1.38 and 3.33 in (B) refer to CSPs that are larger than the displayed range of the plot.
Figure 7.
Figure 7.
SSP based Cα and NH chemical shifts at pH 7.0 (red) and 6.0 (blue) for (A) Apo-S100A12 and, (B) Ca2+-S100A12. The secondary structure of the apoprotein determined from the crystal structure (PDB code 2WCF) is displayed at the top: α-helices (blue bars), β-strands (pink arrows), and loop regions (cyan lines).

References

    1. Donato R, Cannon BR, Sorci G, Riuzzi F, Hsu K, Weber DJ, Geczy CL, Curr. Mol. Med 2013, 13, 24–57. - PMC - PubMed
    1. Gilston BA, Skaar EP, Chazin, Science China: Life Sciences 2016, 59, 792–801; - PMC - PubMed
    2. Zackular JP, Chazin WJ, Skaar EP, J. Biol. Chem 2015, 290, 18991–18998. - PMC - PubMed
    1. Brophy MB, Hayden JA, Nolan EM, J. Am. Chem. Soc 2012, 134, 18089–18100; - PMC - PubMed
    2. Corbin BD, Seeley EH, Raab A, Feldmann J, Miller MR, Torres VJ, Anderson KL, Dattilo BM, Dunman PM, Gerads R, Caprioli RM, Nacken W, Chazin WJ, Skaar EP, Science 2008, 319, 962–965; - PubMed
    3. Hayden JA, Brophy MB, Cunden LS, Nolan EM, J. Am. Chem. Soc 2012, 135, 775–787; - PMC - PubMed
    4. Hayden JA, Brophy MB, Cunden LS, Nolan EM, J. Am. Chem. Soc 2013, 135, 775–787; - PMC - PubMed
    5. Nakashige TG, Zhang B, Krebs C, Nolan EM, Nat. Chem. Biol 2015, 11, 765; - PMC - PubMed
    6. Nakashige TG, Zygiel EM, Drennan CL, Nolan EM, J. Am. Chem. Soc 2017, 139, 8828–8836. - PMC - PubMed
    1. Gläser R, Harder J, Lange H, Bartels J, Christophers E, Schröder J-M, Nat. Immunol 2004, 6, 57; - PubMed
    2. Lee KC, Eckert RL, J. Invest. Dermatol 2007, 127, 945–957; - PubMed
    3. Kehl-Fie TE, Skaar EP, Curr. Opin. Chem. Biol 2010, 14, 218–224; - PMC - PubMed
    4. Cunden LS, Gaillard A, Nolan EM, Chem. Sci 2016, 7, 1338–1348. - PMC - PubMed
    1. Foell D, Seeliger S, Vogl T, Koch H, Maschek H, Harms E, Sorg C, Roth J, Thorax 2003, 58, 613–617; - PMC - PubMed
    2. Larsen A, Bronstein IB, Dahl O, Wentzel-Larsen T, Kristoffersen EK, Fagerhol MK, Scandinavian journal of immunology 2007, 65, 192–201; - PubMed
    3. Kim MH, Choi YW, Choi HY, Myung KB, Cho SN, Br. J. Dermatol 2006, 154, 594–601; - PubMed
    4. Buhimschi IA, Zhao G, Pettker CM, Bahtiyar MO, Magloire LK, Thung S, Fairchild T, Buhimschi CS, Am. J. Obstet. Gynecol 2007, 196, 181.e181–181.e113; - PubMed
    5. Leclerc E, Fritz G, Vetter SW, Heizmann CW, Biochim. Biophys. Acta 2009, 1793, 993–1007. - PubMed

Publication types